Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Igivc

Research Leaders

6 sponsors active, led by Alira Health

Related Conditions

Often studied with 17 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (1)
Phase 4 (1)

Trial Status

Recruiting3
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07761026Recruiting

AXIS MG Patient Registry

NCT06860633Phase 4Recruiting

Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod

NCT06617741Recruiting

Myasthenia Gravis Foundation of America Global MG Patient Registry

NCT02413580Phase 3CompletedPrimary

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

Showing all 4 trials

Research Network

Common Treatments

  • Igivc1
  • Efgartigimod Alfa1

Active Sponsors

  • Alira Health2
  • argenx1
  • Autoimmune Neurology Alliance1
  • Grifols Therapeutics LLC1
  • Myasthenia Gravis Foundation of America1

Top Investigators

Related Conditions

  • Myasthenia Gravis Crisis3
  • Myasthenia Gravis Generalized2
  • Myasthenia Gravis Musk2
  • Myasthenia Gravis Ocular2
  • Myasthenia Gravis Thymectomy2

Activity Timeline